Edition:
Deutschland

Allergan plc (AGN.N)

AGN.N on New York Stock Exchange

158.43USD
18 May 2018
Change (% chg)

$-1.80 (-1.12%)
Prev Close
$160.23
Open
$159.99
Day's High
$161.00
Day's Low
$158.01
Volume
634,843
Avg. Vol
777,163
52-wk High
$256.78
52-wk Low
$142.83

AGN.N

Chart for AGN.N

About

Allergan plc is a specialty pharmaceutical company. The Company is engaged in the development, manufacturing, marketing and distribution of brand name pharmaceutical products, medical aesthetics, biosimilar and over-the-counter pharmaceutical products. The Company operates through three segments: US Specialized Therapeutics, US... (more)

Buy/Sell

Sell Hold Buy
2.09 Mean rating from 23 analysts

Overall

Beta: 1.17
Market Cap(Mil.): $69,117.80
Shares Outstanding(Mil.): 334.31
Dividend: 0.70
Yield (%): 1.35

CORRECTED-UPDATE 3-U.S. FDA approves Amgen drug for prevention of migraines

May 17 Amgen Inc won U.S. Food and Drug Administration approval on Thursday for the first drug in a new class designed to prevent migraine headaches in adults.

Appaloosa gets permission for activist stance with Allergan stake

NEW YORK, May 17 David Tepper's Appaloosa Management and two of his funds received Federal Trade Commission clearance earlier this week that could clear the way for the billionaire to become an activist investor in drugmaker Allergan Plc.

Walgreen, Kroger, Albertsons, HEB sue Allergan over dry-eye drug

NEW YORK, May 16 Allergan Inc was sued on Wednesday by four large U.S. retailers that accused the drugmaker of antitrust violations for trying to stop rivals from selling generic versions of Restasis, its medication to treat dry-eye disease.

UPDATE 3-Evolus investors frown as FDA declines to approve Botox rival

* Deficiencies not related to clinical or non-clinical matters

Photo

Evolus investors frown as FDA declines to approve Botox rival

U.S. health regulators on Wednesday declined to approve Evolus Inc's rival product to Allergan Plc's Botox, citing deficiencies related to the chemistry and manufacturing of its potential treatment for frown lines, sending its shares down as much as 35 percent.

REFILE-FDA declines to approve Evolus Inc's rival treatment to Botox

May 16 U.S. health regulators on Wednesday declined to approve Evolus Inc's rival product to Allergan Plc's Botox, citing certain deficiencies related to its potential treatment for frown lines.

UPDATE 4-U.S. state lawsuits against Purdue Pharma over opioid epidemic mount

NEW YORK, May 15 Litigation against OxyContin maker Purdue Pharma LP is intensifying as six more U.S. states on Tuesday announced lawsuits, accusing the company of fueling a national opioid epidemic by deceptively marketing its prescription painkillers to generate billions of dollars in sales.

BRIEF-Jana Partners LLC Takes Sole Share Stake In Allergan, Boston Scientific

* JANA PARTNERS LLC TAKES SOLE SHARE STAKE IN ALLERGAN PLC OF 12,000 SHARES - SEC FILING

Lilly's migraine drug meets main goal in cluster headache trial

May 15 Eli Lilly and Co said on Tuesday that patients with episodic cluster headache attacks had reduced symptoms when treated with its experimental migraine drug galcanezumab compared to those treated with a placebo.

Märkte

  • U.S.
  • Europa
  • Asien
  • Branchen

Branchenüberblick

Energie +0.03%
Rohstoffe +0.31%
Industrie -0.07%
Konjunktur abhängige Waren & Dienstleistungen -0.44%
Konjunktur unabhängige Waren & Dienstleistungen -0.55%
Finanzindustrie +0.23%
Pharma -0.34%
Technologie -0.57%
Telekommunikation -0.07%

Nachrichten aus der Wirtschaft